Nektar: NKTR-255 for Hematological Malignancies - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if a study drug called NKTR-255 alone or in combination with daratumumab or rituximab is a safe and effective treatment for multiple myeloma or non-Hodgkin lymphoma when it is combined with other drugs.
Relapsed/Refractory Multiple Myeloma and non-Hodgkin lymphoma
Who Can Participate in the Study?
Adults ages 18+ who:
- Have multiple myeloma or non-Hodgkins lymphoma that is not responding to therapy; OR
- Have multiple myeloma or non-Hodgkins lymphoma that has come back after previous therapy
For more information about who can join this study, please contact the study team 919-668-0613.
What is Involved?
There are 2 parts to this study. In Part 1, we will give participants different doses of the study drug to find out what the best dose is. In Part 2, we will only give participants the best dose of the study drug that is determined from Part 1.
Whether or not you are in Part 1 or Part 2 of the study will depend on when you join.
If you choose to join this study in either Part 1 or Part 2, you will:
- Be assigned to 1 of 3 possible study drug regimens
-- You will receive the study drug on its own; OR
-- You will receive the study drug in combination with daratumumab; OR
-- You will receive the study drug in combination with rituximab
Treatment cycles will last for 21 or 28 days. Your study doctor will evaluate how you are doing at the end of each cycle and determine whether or not you should continue.